The prostaglandins are a family of compounds, synthesized in a variety of tissues via a complex enzymatic cascade. In vascular endothelium, arachidonic acid is converted to prostaciclyn (also known as PGI2 or epoprostenol) and PGE2. Nephrologists caring for patients with renal failure have been interested in recent reports of: 1) the ability of prostacyclin infusion to substitute for heparin as an anticoagulant during hemodialysis (1, 2) ; 2) enhanced endogenous prostacyclin production during hemodialysis (3, 4) ; 3) the pressor effect of prostaglandin synthesis inhibition in anephric patients (5) .
Platelet aggregation during contact of blood with dialysis membranes may promote thrombosis in the artificial kidney (6) . The ability of prostacyclin to inhibit platelet aggregation and the availability of synthetic prostacyclin in pharmacologic amounts has led to its substitution for heparin as the sole anticoagulant during hemodialysis. This is appealing to physicians who wish to reduce the hemorrhagic complications of dialysis. Dialysis with prostacyclin can be accomplished without prolongation of conventional coagulation parameters or the template bleeding time. The platelet antiaggregatory effect of prostacyclin, however, can be demonstrated in vitro to persist for several hours after the end of dialysis (1) . This effect might have adverse consequences in patients who are already bleeding. The superiority of prostacyclin over heparin, therefore, must be substantiated by controlled studies comparing the incidence of complications in patients dialyzed with prostacyclin compared to a low-dose heparin technique (7) . As of this writing, the greater safety of prostacyclin remains unproved. Prostacyclin administration can also be limited by its vasodepressor effect (8) . This is due to its potent vasodilatory action. This potentially serious side-effect may be minimized by using bicarbonate instead of acetate-containing dialysate (1) (Smith et al. 1982) . F Further study of the hemodynamic effects of prostacyclin is required in patients with compromised cardiovascular systems, who are often candidates for hemodialysis.
The study of endogenous prostacyclin is hampered by difficulty in measuring its concentration in body fluids.
Because its half-life is extremely short, measurement has been made instead of its more stabble hydrolysis product, 6-keto-PGF1((. As other prostacyclin metabolites are identified, however, reliance on 6-keto-PGF1(( alone as an index of prostacyclin production could be misleading (9) . Adding to the confusion is the problem of interpreting the significance of blood levels of prostaglandins, These substances probably exert their predominant physiologic effects at their sites of synthesis. Whether circulating levels reflect local production is unknown. There is, furthermore, considerable disagreement among published studies as to the blood concentration of 6-keto-PGhx. This may result from important methodologic differences in the measurements (10) . Blood levels of 6keto-Pfif i« rise during hemodialysis (34). The studies cited are contradictory as to wheter this is a consequence of heparin or of the dialysis procedure itself. Heparin can antagonize the platelet antiaggregatory effect of prostacyclin (11) . An increase in endogenous prostacyclin production may thus be compensatory to the heparin effect. It is also possible that heparin could increase prostaglandin production by activating tissue phospholipase (12) with resultant liberation of arachidonic acid from its phospholipid storage sites. Prostacyclin production may also be increased in the lung in response to platelet or leukocyte aggregates which form after contact of blood with the dialysis membrane and lodge in the pulmonary microvasculature. Some of this prostacyclin may be added to the pulmonary venous effluent and thereby reaches the systemic circulation. The consequences of heparin or dialysis -iduced increases in prostacyclin production remain undefined. Enhanced production of vasodilator prostaglandins may account for the hypotensive effect of chronic heparin administration in hypertensive animals (13) , and could contribute to the vasodepressor effect of chronic hemodialysis.
Prostaglandins appear to be involved in the regulation of blood pressure. In blood vessels, prostaglandins may influence peripheral resistance by opposing the vasoconstrictor effects of sympathetic nervous activity and angiotensin. If prostaglandin production were reduced, then the resulting imbalance favoring vasoconstriction would tend to raise blood pressure. The biosynthesis of prostaglandins can be inhibited by the non-steroidal antiinflammatory agents. These drugs block prostaglandins synthesis at an early step, by inhibiting the enzyme eveloxygenase which catalyzes the conversion of arachidonic acid to cyclic endoperoxide intermediates. We recently administered indomethacin to 2 anephric patients with chronic hypotension (5) . Low blood pressure, persisting between dialyses despite salt loading, afflicts a small proportion of chronic dialysis patients. The cause of this condition is unknown (14) . Both of our patients experienced a salutary increase in blood pressure while taking indomethacin, associated with decreases in blood levels of 6-keto-PGF,u and PGE2.
We hypothesized that inhibition of vasodilator prostaglandin synthesis amplified the effects of endogenous pressor stimuli. It is conceivable that hypotension occuring in other dialysis patients, both during and between dialyses, might be mitigated by prostaglandin synthesis inhibition.
Caution is advisable, however, before widespread application of this treatment. Prostaglandins are involved in the stimulation of renal renin secretion. Non-steroidal anti-inflammatory drug may therefore reduce plasma renin activity.
Under certain circumstances, the resultant fall in circulating angiotensin levels may lead to a fall in blood pressure (15) . Because the end-stage kidney may still secrete renin, indomethacin may abrogate a defense mechanism opposing a fall in blood pressure, with unwanted consequences.
In anephric patients, this potential depressor effect of indomethacin could not occur.
The non-steroidal anti-inflammatory drugs may have other undesirable side-effects.
Use of these agents is often limited by the occurrence of abdominal pain, gastrointestinal bleeding, diarrhea, or dizziness due to a central nervous system effect.
It would seem, therefore that manipulation of blood pressure via endogenous prostaglandin synthesis inhibition must await the development of safer and more specific inhibitors.
Synthetic prostaglandin analogues, which may reduce blood pressure, are also being developed.
As prostaglandins come to play increasingly important roles in clinical medicine, it seems likely that they will play important parts in the lives of hemodialysis patients.
